Pharmaceutical industry analyst Andrew Baum is leaving banking to join Pfizer Inc. He will step into the position of chief strategy and innovation officer as an exec VP reporting to CEO Albert Bourla. Baum will have an important role in advancing Pfizer’s long-term corporate strategy, responsible for portfolio analysis and prioritization, business development, partnering and the commercial evaluation of the company’s pipeline.
Key Takeaways
- Former Citi analyst Andrew Baum will join Pfizer beginning 3 June.
- As chief strategy & innovation officer, he will be charged with advancing Pfizer’s long-term corporate strategy, responsible for portfolio analysis and prioritization and business development
He will chair Pfizer’s portfolio management team, the company’s senior governing body responsible for portfolio management and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
